Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells.
AffiliationUniversity of Ulm
MetadataShow full item record
AbstractAcute myeloid leukemia (AML) is the most common acute leukemia in adults. With intensive induction therapy, most patients younger than 60 years achieve complete remission. However, even if these younger patients were treated intensively, more than 50% will relapse. Clinical results of patients older than 60 years are more unfavorable. Therefore, in all patients with AML, the overall survival is still low. In the past decade, several leukemia-associated antigens (LAA) have been identified in patients with acute myeloid leukemia. BAGE, BCL-2, OFA-iLRP, FLT3-ITD, G250, hTERT, PRAME, proteinase 3, RHAMM, survivin, and WT-1 are all LAAs that have been shown to induce CD8+ T-cell recognition and for some antigens also humoral immune responses. Interestingly, most of these LAAs are linked to cell cycle or proliferation. This article discusses the balance between LAA-driven leukemia cell expansion and the elimination of these cells through attacks on LAAs by the immune system. Current knowledge of the function and CD8+ T-cell recognition of LAAs is reviewed and an outlook is given on how to improve T-cell responses to LAAs in acute myeloid leukemia cells.
CitationGreiner, J., Bullinger, L., Guinn, B.A., Döhner, H., Schmitt, M. (2008) 'Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells' Clinical cancer research 14 (22):7161-6
JournalClinical cancer research : an official journal of the American Association for Cancer Research
- Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules.
- Authors: Schmitt M, Li L, Giannopoulos K, Chen J, Brunner C, Barth T, Schmitt A, Wiesneth M, Döhner K, Döhner H, Greiner J
- Issue date: 2006 Dec
- Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens.
- Authors: Li L, Reinhardt P, Schmitt A, Barth TF, Greiner J, Ringhoffer M, Döhner H, Wiesneth M, Schmitt M
- Issue date: 2005 Jul
- Peptide vaccines for patients with acute myeloid leukemia.
- Authors: Schmitt M, Casalegno-Garduño R, Xu X, Schmitt A
- Issue date: 2009 Oct
- Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens.
- Authors: Greiner J, Döhner H, Schmitt M
- Issue date: 2006 Dec
- Autologous peptides eluted from acute myeloid leukemia cells can be used to generate specific antileukemic CD4 helper and CD8 cytotoxic T lymphocyte responses in vitro.
- Authors: Delluc S, Tourneur L, Michallet AS, Boix C, Varet B, Fradelizi D, Guillet JG, Buzyn A
- Issue date: 2005 Aug